Chronic kidney disease-
mineral bone disorders (
CKD-MBD) exhibit abnormalities in the circulating
mineral levels,
vitamin D metabolism, and parathyroid function that contribute to the formation of a bone lesion. The uremic toxin,
indoxyl sulfate (IS), accumulates in the blood in cases of
renal failure and leads to bone loss. The bone and renal responses to the action of the
parathyroid hormone (PTH) are progressively decreased in CKD in spite of increasing PTH levels, a condition commonly called PTH resistance. There is a high prevalence of low bone turnover or adynamic
bone disease in the early stages of CKD. This could be due to the inhibition of bone turnover, such as in PTH resistance, reduced active
vitamin D levels, diabetes,
aluminum, and, increased IS. With an increase in IS, there is a decrease in the osteoblast Wnt/b-
catenin signaling and increase in the expression of Wnt signaling inhibitors, such as sclerostin and Dickkopf-1 (DKK1). Thus, a majority of early CKD patients exhibit deterioration of bone quality owing to the action of IS, this scenario could be termed uremic
osteoporosis. However, this mechanism is complicated and not fully understood. With progressive deterioration in the renal function, IS accumulates along with persistent PTH secretion, potentially leading to high-turnover bone disease because high serum PTH levels have the ability of overriding peripheral PTH resistance and other inhibitory factors of bone formation. Finally, it leads to deterioration in bone quantity with prominent
bone resorption in
end stage renal disease.
Uremic toxins adsorbents may decelerate oxidative stress and improve bone health in CKD patients. This review article focuses on IS and bone loss in CKD patients.